Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains

Haematologica

Volumn 92, Issue 1, 2007, Pages 143-144

  Dawson, Mark A ^a,c   Patil, Sushrut ^b   Spencer, Andrew ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH CHILDREN S HOSPITAL   (Australia)

^c The Alfred   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENCE JONES PROTEIN; CISPLATIN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MELPHALAN; PAMIDRONIC ACID; PREDNISOLONE; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; CLINICAL FEATURE; CONSTIPATION; DISEASE ACTIVITY; DISEASE COURSE; DRUG MEGADOSE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MULTIPLE MYELOMA; SOMNOLENCE; TREATMENT RESPONSE;

AGED; BENCE JONES PROTEIN; BETA 2-MICROGLOBULIN; CHEMISTRY, CLINICAL; FEMALE; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULINS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; RECURRENCE; RNA, MESSENGER;

EID: 33846894539     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10297     Document Type: Article

References (12)

1. McIntyre OR. Laboratory Investigation of myeloma In: Myeloma Biology and Managemen. Oxford University Press, New York. 1995. p. 191-221.
2. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004;126:348-54.
3. Tate J, Mollee P, Gill D. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2005;128:405-6.
4. Nishida K, Tamura A, Nakazawa N, Ueda Y, Abe T, Matsuda F, et al. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 1997;90:526-34.
5. Szczepanski T, van 't Veer MB, Wolvers-Tettero IL, Langerak AW, van Dongen JJ. Molecular features responsible for the absence of immunoglobulin heavy chain protein synthesis in an IgH(-) subgroup of multiple myeloma. Blood 2000;96:1087-93.
6. Magrangeas F, Cormier ML, Descamps G, Gouy N, Lode L, Mellerin MP, et al. Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. Blood 2004; 103:3869-75.
7. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2332-6.
8. Rasmussen T. The presence of circulating clonal CD19+ cells in multiple myeloma. Leuk Lymphoma 2001;42:1359-66.
9. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73.
10. Raanani P, Shpilberg O, Ben-Bassat I. Extramedullary disease and targeted therapies for hematological malignancies - is the association real¿ Ann Oncol 2006[Epub ahead of print].
11. Balleari E, Ghio R, Falcone A, Musto P. Possible multiple myeloma dedifferentiation following thalidomide therapy: a report of four cases. Leuk Lymphoma 2004;45:735-8.
12. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-80.